{"entity":{"id":"ace-106","kind":"drug","name":"ACE-106","aka":["ACE-86225106"],"tldr":"ACE-106 is an experimental oral small-molecule inhibitor from Acerand Therapeutics, in phase 2 trials for advanced solid tumours and BRCA-mutated ovarian, breast and prostate cancer.","summary":"ACE-106 (ACE-86225106) is an oral small-molecule inhibitor from Acerand Therapeutics. A highly selective PARP1 inhibitor taken by mouth. Its furthest stage is phase 2, for advanced solid tumours and BRCA-mutated ovarian, breast and prostate cancer (registry conditions). ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06380660 (sponsor Acerand Therapeutics (Shanghai)) active, not recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Acerand Therapeutics: acerand.com","url":"https://www.acerand.com/news.html"},{"label":"Acerand Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06380660"},{"label":"ClinicalTrials.gov: trials of ACE-106","url":"https://clinicaltrials.gov/search?intr=ACE-106"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":[],"companies":["acerand-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06380660"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ACE-106","modality":"Oral small-molecule inhibitor","mechanism":"A highly selective PARP1 inhibitor taken by mouth.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ace-106/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"company":[{"id":"acerand-therapeutics","kind":"company","name":"Acerand Therapeutics","route":"/companies/acerand-therapeutics/"}],"trial":[{"id":"nct06380660","kind":"trial","name":"Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors","route":"/trials/nct06380660/"}]}}